Results of the meeting of the Interdisciplinary Expert Council on an integrated approach to the management of peri- and postmenopausal women with psycho-emotional and neurological disorders
Authors:
- V.Y. BalanVBV.Y. Balan
- M.I. YarmolinskayaMYM.I. Yarmolinskaya
- S.V. YurenevaSYS.V. Yureneva
- M.A. SamushiyaMSM.A. Samushiya
- A.V. SergeevASA.V. Sergeev
- G.R. TabeevaGTG.R. Tabeeva
- A.R. ArtemenkoAAA.R. Artemenko
- I.S. PreobrazhenskayaIPI.S. Preobrazhenskaya
- Z.R. GardanovaZGZ.R. Gardanova
- V.V. KorennayaVKV.V. Korennaya
- Y.B. SkibaYSY.B. Skiba
- O.B. TalibovOTO.B. Talibov
- 7 August 2026
- journal article
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (7)
Abstract
The reduction in sex hormone levels during the menopausal period substantially impacts patients’ quality of life and serves as a significant risk factor for psycho-emotional disorders. Current clinical guidelines from both Russian and international sources recognize menopausal hormone therapy (MHT) as the primary method for addressing menopausal disorders. However, selecting dosage forms tailored to the patient’s comorbidities and overall health status is essential. In 2026, the Russian Association of Obstetricians and Gynecologists, the Interdisciplinary Association of Specialists in Healthy Aging and Anti-Aging Medicine, and the Russian Society for the Study of Headache established an interdisciplinary council to implement an integrated approach to the management of peri- and postmenopausal women with psycho-emotional and neurological disorders. The objectives of the expert council included discussing contemporary management strategies for peri- and postmenopausal women and optimizing the application of MHT in complex clinical cases. Additionally, the council aimed to enhance scientific methodologies and devise algorithms for managing patients presenting with menopausal symptoms due to estrogen deficiency, alongside neurological and psycho-emotional disorders. The collaborative efforts of the experts culminated in a consensus document that outlines key principles for the administration of MHT to women with psycho-emotional disorders and somatic comorbidities during the peri- and postmenopausal stages.Keywords
This publication has 67 references indexed in Scilit:
- FIGO best practice recommendations for the mental health of women at menopausal ageInternational Journal of Gynecology & Obstetrics, 2026
- Menopause, Perimenopause, and Migraine: Understanding the Intersections and Implications for TreatmentNeurology and Therapy, 2025
- Diagnostic and therapeutic use of oral micronized progesterone in endocrinologyReviews in Endocrine and Metabolic Disorders, 2024
- Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paperInternational Journal of Gynecology & Obstetrics, 2024
- The risk of depressive and anxiety symptoms in women with premature ovarian insufficiency: a systematic review and meta-analysisArchives of Women's Mental Health, 2023
- Hormonal Agents for the Treatment of Depression Associated with the MenopauseDrugs & Aging, 2022
- Estrogen, brain structure, and cognition in postmenopausalwomenHuman Brain Mapping, 2020
- Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause TransitionJAMA Psychiatry, 2018
- Migraine headache in perimenopausal and menopausal womenCurrent Pain and Headache Reports, 2009
- Efficacy of Estradiol for the Treatment of Depressive Disorders in Perimenopausal WomenArchives of General Psychiatry, 2001